Mangalam Drugs & Organics Limited

NSE MANGALAM.NS

Mangalam Drugs & Organics Limited EBIT for the year ending March 31, 2024: USD -79.67 K

Mangalam Drugs & Organics Limited EBIT is USD -79.67 K for the year ending March 31, 2024, a -104.38% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Mangalam Drugs & Organics Limited EBIT for the year ending March 31, 2023 was USD 1.82 M, a -64.45% change year over year.
Mangalam Drugs & Organics Limited EBIT for the year ending March 31, 2022 was USD 5.12 M, a -23.14% change year over year.
Mangalam Drugs & Organics Limited EBIT for the year ending March 31, 2021 was USD 6.66 M, a 217.74% change year over year.
Mangalam Drugs & Organics Limited EBIT for the year ending March 31, 2020 was USD 2.10 M, a 401.02% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NSE: MANGALAM.NS

Mangalam Drugs & Organics Limited

CEO	Mr. Govardhan Murlidhar Dhoot
IPO Date	May 23, 2005
Location	India
Headquarters	Rupam Building
Employees	432
Sector	Healthcare
Industries Pharmaceuticals Chemicals & Advanced Materials Cleaning Supplies Drugstores & Retail Pharmacies Personal Care Petrochemicals

Description

Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.

Key trends

Past 5 years